CRMD
CorMedix Inc. Healthcare - Biotechnology Investor Relations →
CorMedix Inc. (CRMD) closed at $7.53 as of 2026-07-31, trading 8.3% above its 200-week moving average of $6.95. The stock is currently moving closer to the line, down from 13.6% last week. The 14-week RSI sits at 51, indicating neutral momentum.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.77 ratio) is neutral — neither side is clearly dominating.
Over the past 798 weeks of data, CRMD has crossed below its 200-week moving average 18 times. On average, these episodes lasted 26 weeks. The average one-year return after crossing below was -3.9%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $591 million, CRMD is a small-cap stock. The company generates a free cash flow yield of 20.3%, which is notably high. Return on equity stands at 65.6%, indicating strong profitability. The stock trades at 1.4x book value.
Share count has increased 85.1% over three years, indicating dilution. CRMD passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 15.3 years, a hypothetical investment of $100 in CRMD would have grown to $80, compared to $716 for the S&P 500. CRMD has returned -1.4% annualized vs 13.7% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CRMD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CRMD Crosses Below the Line?
Across 18 historical episodes, buying CRMD when it crossed below its 200-week moving average produced an average return of -7.2% after 12 months (median -25.0%), compared to +13.1% for the S&P 500 over the same periods. 29% of those episodes were profitable after one year. After 24 months, the average return was -25.9% vs +33.0% for the index.
Each line shows $100 invested at the moment CRMD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices CRMD would reach each dislocation threshold.
Dislocation Price Levels
Prices where CRMD's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-08-06.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $4.30 | Unusually cheap — potential buy zone |
| Value | +1σ | $5.09 | Cheap vs. own history |
| Fair Value | +0σ | $6.23 | Historical mean behavior |
| Expensive | -1σ | $8.04 | Expensive vs. own history |
| Deep Expensive | -2σ | $11.31 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from CRMD's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
CRMD has crossed below its 200-week MA 18 times with an average 1-year return of +-3.9% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 2011 | Apr 2011 | 1 | 0.8% | -79.5% | -14.4% |
| May 2011 | Dec 2013 | 137 | 85.1% | -82.9% | -11.4% |
| Dec 2015 | Dec 2015 | 1 | 2.1% | -5.4% | -18.2% |
| Jan 2016 | Feb 2016 | 8 | 35.7% | +6.1% | -8.7% |
| Jun 2016 | Sep 2016 | 14 | 32.9% | -80.0% | -30.0% |
| Oct 2016 | Jan 2019 | 120 | 91.8% | -72.2% | -34.5% |
| Feb 2019 | Feb 2019 | 1 | 1.1% | -25.4% | -10.9% |
| May 2019 | Jun 2019 | 3 | 10.6% | -36.3% | +9.4% |
| Sep 2019 | Dec 2019 | 11 | 22.0% | -22.2% | +12.7% |
| Jan 2020 | Feb 2020 | 1 | 0.2% | +37.8% | +18.6% |
| Feb 2020 | Jun 2020 | 14 | 54.2% | +188.5% | +44.8% |
| Jul 2020 | Sep 2020 | 8 | 24.0% | +30.6% | +69.2% |
| Oct 2020 | Nov 2020 | 1 | 1.5% | -3.8% | +49.1% |
| Jul 2021 | Aug 2021 | 1 | 0.5% | -7.9% | +29.6% |
| Aug 2021 | Aug 2021 | 1 | 0.2% | -33.4% | +28.3% |
| Sep 2021 | Apr 2024 | 135 | 56.2% | -19.7% | +62.6% |
| May 2024 | Aug 2024 | 14 | 25.7% | +139.8% | +47.1% |
| Mar 2026 | Mar 2026 | 3 | 4.9% | N/A | +16.6% |
| Average | 26 | — | +-3.9% | — |
Frequently Asked Questions
Is CRMD below its 200-week moving average?
No. CorMedix Inc. (CRMD) is currently 8.3% above its 200-week moving average of $6.95. It would need to fall to $6.95 to cross below the line.
What is CRMD's 200-week moving average price?
CorMedix Inc.'s 200-week moving average is $6.95 as of 2026-07-31. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CRMD drops below its 200-week moving average?
CRMD has crossed below its 200-week moving average 18 times in our data. The average one-year return after these crossings was -3.9%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 26 weeks on average.
Is CRMD a good value right now?
Here's what our data says about CRMD as of 2026-07-31: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 51. Free cash flow yield is 20.3%. Return on equity is 65.6%. Price-to-book is 1.4x. This is not a buy or sell recommendation — always do your own research.
How does CRMD compare to the S&P 500?
Over the past 15.3 years, $100 invested in CRMD would have grown to $80, compared to $716 for the S&P 500. That's -1.4% annualized vs 13.7% for the index. CRMD has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-07-31